Leadership
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Giant LEAPS For Mankind: Bayer's Malik On Breaking The Mold In R&D
As new scientific breakthroughs are shaking the foundations of pharma and biotech R&D, In Vivo sat down with Bayer's Kemal Malik to hear how the German big pharma is responding to the challenges with its ground-breaking LEAPS program.
Latest From Leadership
Gene Therapy: Spark Charts A Course From Science To Payer And Patient Satisfaction
Gene therapy’s promise depends on the ecosystem now being built to deliver real product to patients – safely and at quantities that match the soaring expectations fed by the curative potential of the science. To assess the state of play, In Vivo talks to the man who leads the team responsible for bringing forward the first US-approved gene therapy to treat an incurable, inherited genetic condition: John Furey, chief operating officer of Spark Therapeutics.
Drug Delivery Outsourcing In A World Of Pharma’s Shifting Sands
The contract drug delivery industry is facing disruptive influences from an evolving client base, the increase in biologics manufacturing and specialty pharma needs. In Vivo speaks to Catalent’s vice president of strategy, Cornell Stamoran, about the evolution of the industry and the continuous search for efficiency.
Bringing The Clinician's Rationale Into The Heart Of Strategic Decision-Making At Boston Scientific
Boston Scientific Corp. has been back on the M&A trail in a big way in 2018, with a succession of strategic additions of various sizes that all have potential patient and shareholder impact across – and beyond – its established divisions. Chief medical officer of 18 months Ian Meredith explains the thought processes driving this policy, and the added dimension a CMO can bring to the overall question of strategy.
Broader Capabilities Keep Consort On Top At Device End Of Drug Delivery
Drug delivery technology specialist Consort Medical has capitalized on device respiratory expertise for 50 years, but a renewed focus on strategic expansion has seen it make an IP play, move into the pharma side and target other delivery formats for global pharma industry customers. Its enhanced capabilities will keep rivals on their toes.
Moving Medical Affairs To The Pharma Forefront
Straddling the R&D and commercial sides of a typical pharma organization means medical affairs is naturally positioned to play an expanded role along the full pharma value chain. The combination of exploding data from internal and external sources, and a stronger focus on value and outcomes, has reshaped the requirements and expectations for drug development and commercialization businesses.
Execs On The Move, July 2018
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.